SSZ is a multitarget inhibitor that addresses various pathological mechanisms in Alzheimers disease (AD). It targets acetylcholinesterase (acetylcholinesterase), butyrylcholinesterase (butyrylcholinesterase), β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), and γ-secretase (γ-secretase). In murine models, SSZ has been shown to improve Alzheimers disease and exhibit neuroprotective effects.